Le Lézard
Classified in: Science and technology, Business
Subject: ATY

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of INSTRUCTURE, INC - INST


NEW YORK, Dec. 6, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Instructure, Inc. ( the "Company") (Nasdaq: INST) relating to the sale of the Company to PIV Purchaser, LLC. Under the terms of the Merger, each share of Instructure common stock will automatically be converted into the right to receive $47.60 in cash for each share of Instructure common stock owned. 

Monteverde & Associates PC Logo

The investigation focuses on whether Instructure, Inc and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's by 1) failing to conduct a fair process and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/instructure-inc. It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.

If you own common stock in Instructure, Inc and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
[email protected] 
Tel: (212) 971-1341

Attorney Advertising. (C) 2019 Monteverde & Associates PC.  The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC


These press releases may also interest you

at 08:48
SpeechWare of Brussels has announced the launch of the next-generation TableMike®, which natively operates with Dolbey's state-of-the-art speech recognition technology, Fusion Narrate® powered by nVoqtm. The TableMike, paired with Fusion Narrate,...

at 08:48
Snappt, the leader in document fraud detection for residential apartment property managers, today announced the company's partnership with ResidentIQ®, an industry leader offering a comprehensive suite of software that integrates with property...

at 08:46
Classic Custom Carts, a golf cart company located in Indiana, has just launched a new website and opened a new location in Salisbury, North Carolina. The new website, www.classiccustomcarts.com, is designed to be a one stop shop for golf cart...

at 08:45
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd. (Braingaze) and...

at 08:45
Stem , a leader in AI-driven clean energy solutions and services, will hold a conference call on Thursday, May 2, 2024, to discuss its results for the quarter ended March 31, 2024. The conference call is scheduled to begin at 5:00 p.m. Eastern...

at 08:45
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the pricing of its "reasonable best efforts" public offering of 15,197,500 shares of common stock (or...



News published on and distributed by: